galactosyl-(1-3)galactose has been researched along with Malignant Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| A'Hern, RP; Eisen, TG; Gore, ME; Larkin, JM; Norsworthy, PJ; Porter, CD | 1 |
| Jäger, U; Porter, CD; Takeuchi, Y | 1 |
2 other study(ies) available for galactosyl-(1-3)galactose and Malignant Melanoma
| Article | Year |
|---|---|
Anti-alphaGal-dependent complement-mediated cytotoxicity in metastatic melanoma.
Topics: Adult; Antibodies; Antibody Specificity; Complement System Proteins; Cytotoxicity, Immunologic; Disaccharides; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunodiffusion; Immunoglobulin G; Immunoglobulin M; Male; Melanoma; Middle Aged | 2006 |
Sensitization of human cells to lysis by human complement as an approach for cancer gene therapy.
Topics: 3T3 Cells; Animals; Cell Line; Cell Membrane; Complement System Proteins; Disaccharides; Galactosyltransferases; Genetic Therapy; Genetic Vectors; Humans; Melanoma; Mice; Phosphatidylinositol Diacylglycerol-Lyase; Retroviridae; Tumor Cells, Cultured; Type C Phospholipases | 1998 |